A quick apology to readers of this blog. I really enjoy writing here, but the past month has thrown up a number of challenges. One of these challenges is actually finding something interesting and, importantly, new, to write about. There are so many bloggers out there that I feel I would be doing you a […]Read More Balloon animals
I probably don’t need to tell you that there has been buzz recently about the new FDA guidance on social media that is predicted to appear in this year Indeed, John Mack predicted that the guidance would be issued in sections, and he puts forward a theory that guidance on short-format or space-limited communications will […]Read More Social media sharing for pharma
I want to pick up a bit more on the closing remark from my DigiPharm Europe 2010 posts. If you recall, I said: To survive in this landscape, Pharma must make inroads into developing a digital strategy – and by that I mean integrate your digital tactics into your overall strategic plan, and at the […]Read More When is digital strategy not digital strategy?
Here’s my final post on the #DigiPharm narrative. Part 7! Again, I am reporting on selected sessions from Day 2, ones that I found of note or interest. You can read the twitterstream for more information on the presentations not covered here. Part 1 Part 2 Part 3 Part 4 Part 5 Part 6 Still […]Read More DigiPharm Europe 2010 Pt 7
So here’s the penultimate part of this week-long series. Today I am focusing on the morning session of Day 2 of DigiPharm 2010 and the concluding blog post tomorrow will cover the afternoon session. I will not cover every presentation from Day 2, just the ones that had impact with the audience. Part 1 Part […]Read More DigiPharm Europe 2010 Pt 6